Original triazine inductor of new specific molecular targets, with antitumor activity against nonsmall cell lung cancer

International Journal of Cancer

Volumn 123, Issue 11, 2008, Pages 2676-2683

  Moreau, Dimitri ^a   Jacquot, Catherine ^a   Tsita, Polyxeni ^b   Chinou, Ioanna ^b   Tomasoni, Cristophe ^a   Juge, Marcel ^a   Antoniadou Vyza, Ekaterini ^b   Martignat, Lionel ^a   Pineau, Alain ^a   Roussakis, Christos ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Antiproliferative; Apoptosis; Bronchopulmonary cancer; Molecular targets; Regulatory RNA

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 1 (4'' CHLOROPHENYL) 2 (1 TRICYCLO[3.3.1.1 3,4 ] DECYL 1,3,5 TRIAZINE; A 190; ANTINEOPLASTIC AGENT; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B2 GENE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; CYTOSTASIS; DRUG MECHANISM; DRUG TARGETING; FEMALE; GENE; HEF1 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; MOLECULAR THERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; MOLECULAR STRUCTURE; PHOSPHOPROTEINS; TRIAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57349164235     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23809     Document Type: Article

References (58)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8.
2. Ettinger DS. Overview and state of the art in the management of lung cancer. Oncology (Williston Park, NY) 2004;18:3-9.
3. Lilenbaum RC, Herndon Ii JE, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, Weeks JC, Holland JC, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 2005;23:190-6.
4. Ettinger DS. Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer? Oncologist 2002;7:226-33.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
7. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-84.
8. Ramalingam S, Belani CP. Carboplatin/gemcitabine combination in advanced NSCLC. Oncology (Williston Park, NY) 2004;18:21-6.
9. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004;15:19-27.
10. Eckhardt S. Molecular targeted therapy: a strategy of disillusions or optimism? J Lab Clin Med 2006;147:108-13.
11. Ardizzoni A, Tiseo M. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). J Chemother 2004;16:104-7.
12. Dubey S, Schiller JH. Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab. Oncologist 2005;10:282-91.
13. Jacquot C, Moreau D, Tomasoni C, Juge M, Coiffard L, Roussis V, Roussakis C. Proliferation arrest in G1 phase of a non-small cell lung cancer cell line (NSCLC-N6) treated by an original compound methyl-4-methoxy-3-(3-methyl-2- butanoyl) benzoate (VT1) independently of the p53/p21 cascade. Int J Oncol 2003;23:495-501.
14. Moreau D, Tomasoni C, Jacquot C, Kaas R, Le Guedes R, Cadoret J-P, Muller-Feuga A, Kontiza I, Vagias C, Roussis V, Roussakis C. Cultivated microalgae and the carotenoid fucoxanthin from Odontella aurita as potent anti-proliferative agents in bronchopulmonary and epithelial cell lines. Environ Toxicol Pharmacol 2006;22:97-103.
15. Siavoshian S, B€oesh S, Riou D, Dabouis G, More MT, Pondaven P, Roussakis C. Cloning of a human cancer cell line (NSCLC-N6) and comparative study of these clones in vitro. Anticancer Res 1998;18:193-200.
16. Zimmermann PV, Hawson GAT, Bint HH, Parsons PG. Ploidy as a pronostic determinant in surgically treated lung cancer. Lancet 1987;2:530-3.
17. Salvati F, Teodori L, Gagliardi L, Signora M, Aquilini M, Storniello G. DNA flow cytometric studies of 66 human lung tumors analyzed before treatment. Chest 1989;96:1092-8.
18. Maurer HR, Eckert K, Bissery MC. Taxotere inhibits the proliferation and induces the differentiation of HL-60 and K562 human myeloid leukemia cell in vitro. Int J Oncol 1993;3:161-5.
19. Lotan R, Francis GE, Freeman CS, Vaxman S. Differentiation therapy. Cancer Res 1990;50:3453-64.
20. Wille JJ, Scott RE. Topography of the predifferentiation GD growth arrest state relative to other growth arrest states in the G1-phase of the cell cycle. Int J Cell Physiol 1982;112:115-22.
21. Roussakis C, Gratas C, Audouin AF, Boterff JL, Dabouis C, Andre MJ, Moyon E, Vo NH, Pradal G, Verbist JF. Study of in vitro drug sensitivity on a newly established cell line from a primary bronchial epidermoÿd carcinoma of huma origin (NSCLC-N6). Anticancer Res 1991;11:2239-44.
22. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973;51:1417-23.
23. Ahmad SI, Kirk SH, Eisenstark A. Thymine metabolism and thymineless death of procaryotes and eucariotes. Annu Rev Microbiol 1997;52:591-625.
24. Rosowsky A, Wright JE, Ginty C, Uren J. Methotrexate anbalogues. 15. A methotrexate analogue designed for active-site-directed irreversible inactivation of DHFR. J Med Chem 1982;25:960-9.
25. Blaney JM, Hansch C, Silipo C, Vittoria C. Structure-activity relationships of Dihydrofolate reductase inhibitors. Annu Chem Rev 1984;84:333-73.
26. Baker BR, Ashton WT. Irreversible enzyme inhibitors. 197. Water soluble reversible inhibitors of DHFR with potent antitumor activity derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine. J Med Chem 1970;13:1165-70.
27. Modest EJ, Levine F. Chemical and biological studies on 1,2-s-triazines. II. Two component synthesis. J Org Chem 1956;21:1-13.
28. Fashena SJ, Einarson MB, O'Neill GM, Patriotis C, Golemis EA. Dissection of HEF1-dependent functions in motility and transcriptional regulation. J Cell Sci 2002;115:99-111.
29. Law SF, O'Neill GM, Fashena SJ, Einarson MB, Golemis EA. The docking protein HEF1 is an apoptotic mediator at focal adhesion sites. Mol Cell Biol 2000;20:5184-95.
30. Jacquot C, Carbonnelle D, Tomasoni C, Papaconstadinou A, Roussis V, Roussakis C. Identification of a novel putative non-coding RNA involved in proliferation arrest of a non-small cell lung carcinoma cell line treated with an original chemical substance, methyl-4-methoxy-3-(3-methyl-2-butanoyl) benzoate. Int J Oncol 2004;25:519-27.
31. Liu AY, Torchia BS, Migeon BR, Siliciano RF. The human NTT gene: identification of a novel 17-kb noncoding nuclear RNA expressed in activated CD41 T cells. Genomics 1997;39:171-84.
32. Alexandropoulos K, Baltimore D. Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel p130Cas-related protein, Sin Genes Development 1996;10:1341-55.
33. Ishino M, Ohba T, Sasaki H, Sasaki T. Molecular cloning of a cDNA encoding a phosphoprotein, Efs, which contains a Src homology 3 domain and associates with Fyn. Oncogene 1995;11:2331-8.
34. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H, Yazaki Y, Hirai H. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J 1994;13:3748-56.
35. Law SF, Estojak J, Golemis EA, Wang B, Mysliwiec T, Kruh G. Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol 1996;16:3327-37.
36. Manie SN, Astier A, Canty T, Avraham H, Haghayeghi N, Sattler M, Salgia R, Freedman AS, Beck ARP, Law SF, Golemis EA, Hirai H, et al. Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J Biol Chem 1997;272:4230-6.
37. Minegishi M, Tachibana K, Sato T, Iwata S, Nojima Y, Morimoto C. Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in β1 integrin-mediated signaling in lymphocytes. J Exp Med 1996;184:1365-75.
38. Nojima Y, Morino N, Mimura T, Hamasaki K, Furuya H, Sakai R, Sato T, Tachibana K, Morimoto C, Yazaki Y, Hirai H. Integrin-mediated cell adhesion promotes tyrosine phosphorylation of p130(Cas), a Src homology 3-containing molecule having multiple Src homology 2-binding motifs. J Biol Chem 1995;270:15398-402.
39. Vuori K, Ruoslahti E. Tyrosine phosphorylation of p130(Cas) and cortactin accompanies integrin-mediated cell adhesion to extracellular matrix. J Biol Chem 1995;270:22259-62.
40. Law SF, Zhang YZ, Klein-Szanto AJ, Golemis EA. Cell cycle-regulated processing of HEF1 to multiple protein forms differentially targeted to multiple subcellular compartments. Mol Cell Biol 1998;18:3540-51.
41. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell 1996;84:359-69.
42. O'Neill GM, Golemis EA. Proteolysis of the docking protein HEF1 and implications for focal adhesion dynamics. Mol Cell Biol 2001;21:5094-108.
43. Boudreau N, Bissell MJ. Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr Opin Cell Biol 1998;10:640-6.
44. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-26.
45. Carelli S, Zadra G, Vaira V, Falleni M, Bottiglieri L, Nosotti M, Di Giulio AM, Gorio A, Bosari S. Up-regulation of focal adhesion kinase in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 2006;53:263-71.
46. Suzuki K, Takahashi K. Reduced cell adhesion during mitosis by threonine phosphorylation of b1 integrin. J Cell Physiol 2003;197:297-305.
47. Sawin KE, Endow SA. Meiosis, mitosis and microtubule motors. Bioessays 1993;15:399-407.
48. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
49. Vindelov LL. Flow microfluorimetric analysis of nuclear DNA in cells from solid tumors and cells suspensions. A new method for rapid isolation and staining of nuclei. Virshows Arch B Cell Pathol 1977;24:227-42.
50. Fried J, Mandel M. Multi-user system for analysis of data from flow cytometry. Comput Program Biomed 1979;10:218-30.
51. Barlogie B, Drewinko B, Johnston DA, Buchner T, Hauss WH, Freireich EJ. Pulse cytophotometric analysis of synchronised cells in vitro. Cancer Res 1976;36:1176-81.
52. Sokal RR, Rohlf FJ. Biometry: the principles and practice of statistics in biological research, 3th edn. New York: Freeman W.H., 1995.
53. Liscia E, Riou D, Siavoshian S, Boesh S, Dabouis G, Biard JF, Roussakis C. Terminal differentiation in a non-small-cell bronchopulmonary carcinoma correlates with increased expression of p53. Anticancer Res 1996;16:1209-12.
54. Siavoshian S, Jacquot C, Biard JF, Briand G, Roussakis C. Substractive hybridisation and differential screening identified two genes differentially expressed after induction of in vitro (atypical) terminal differentiation in the NSCLC-N6 cell line by a marine substance (bistramide K). Anticancer Res 1999;19:5361-6.
55. Carbonnelle D, Jacquot C, Lanco X, Le Dez G, Tomasoni C, Briand G, Tsotinis A, Calogeropoulou T, Roussakis C. Up-regulation of a novel mRNA (NY-CO-1) involved in the methyl 4-methoxy-3-(3-methyl-2-butenoyl) benzoate (VT1)-induced proliferation arrest of a non-small-cell lung carcinoma cell line (NSCLC-N6). Int J Cancer 2001;92:388-97.
56. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007;448:807-10.
57. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, Brennan C, Hahn WC, Cordon-Cardo C, Wagner SN, Flotte TJ, Duncan LM, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006;125:1269-81.
58. Singh M, Cowell L, Seo S, O'Neill G, Golemis E. Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell Biochem Biophys 2007;48:54-72.